Celera Corp. – Aggressive Growth – Zacks Rank Buy
Source: http://www.zacks.com/commentary/9668/Celera+Corp.+-+Aggressive+Growth+-+Zacks+Rank+BuyPosted on Tuesday, January 6th, 2009 | In Stocks to Watch
Celera Corp. (CRA) is showing phenomenal growth over the next few years as shares continue to set higher highs.
Company Description
| < ?DART(15);?> |
Celera Corp. is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and optimize patient management.
The company also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases.
Modest Earnings…For Now
On Oct 28 Celera reported third-quarter results for calendar 2008 that included net revenues of $45.8 million, up from just $16.1 in the same quarter last year. All of the revenue growth was due to the acquisition of Berkeley HeartLab and Atria Genetics, which were bought nearly one year ago.
Earnings per share came to 1 cent per share, which met analyst expectations.
Explosive Growth Ahead
After teetering on the bring of profitability over the past few quarters, consensus estimates are relatively through the roof. The average estimate for the current fiscal year, which ends in June, is 11 cents, up from breaking even last year.
More impressively is the 37 cents per share projected for fiscal 2010, a 233% growth rate.
The Chart
Shares of CRA have broken through two levels of resistance it formed a nice trend. The stock continues to set higher highs and higher lows after it stabilized near $8 per share when setting its 52-week low. Take a look at the chart below.
“CRA” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- VIP Falls Behind Expectations - Analyst Blog - November 25th, 2009
- J. Crew Beats Zacks Estimates - Analyst Blog - November 25th, 2009
- No Change in Deere's Outlook - Analyst Blog - November 25th, 2009
- Sprint Acquires Virgin Mobile USA - Analyst Blog - November 25th, 2009
- Provenge Action Date Assigned - Analyst Blog - November 25th, 2009
Abbott;, Atria Genetics;, Berkeley HeartLab;, cancer, cardiovascular disease, Celera Corp;, cent;, healthcare business delivering;, licensed other relevant diagnostic technologies;, liver diseases;, molecular diagnostic products, relevant diagnostic technologies;, Stocks to Watch, USD, Zacks Market Commentaries, Zacks Rank Buy Celera Corp.;
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.